Nasopharyngeal Carcinoma, Nutrition Therapy
Conditions
Brief summary
This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy of standard nutrition treatment versus conventional nutrition treatment in local advanced nasopharyngeal carcinoma patients.
Interventions
OTHERStandardized nutrition therapy
Standardized nutrition therapy with ONS, nasal feeding tube, PEG or parenteral nutrition
DRUGCisplatin
Patients in both arms received concurrent cisplatin chemotherapy:100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
RADIATIONIntensity Modulated Radiation Therapy
Patients in both arms received Intensity Modulated Radiation Therapy:All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose was 70-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-70 Gy to PTVnd (Planning target volume of the cervical lymph node),60- 64Gy to PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
Sponsors
Sun Yat-sen University
Zhongnan Hospital
The First Affiliated Hospital of Xiamen University
Fudan University
Jiangxi Provincial Cancer Hospital
Xijing Hospital
Xiangya Hospital of Central South University
Fujian Cancer Hospital
Zhejiang Cancer Hospital
Cancer Hospital of Guizhou Province
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III); * All genders，range from 18～65 years old; * Karnofsky performance status(KPS) ≥ 80; * Clinical stage III\~IVa(AJCC/UICC 8th); * Without significant digestive system disease，nutritional and metabolic diseases or endocrine disease * Without significant cardiac，respiratory，kidney or liver disease; * Not received radiotherapy, chemotherapy and other anti-tumor treatment(including immunotherapy); * White blood cell(WBC) count ≥ 4×109/L, neutrophile granulocyte(NE) count ≥ 1.5×109/L, Hemoglobin(HGB) ≥ 9g/L, platelet(PLT) count ≥ 100×109/L * Total bilirubin(TBIL)、alanine aminotransferase (ALT) or aspartate aminotransferase(AST) \< 2.5×upper limit of normal(ULN); * Adequate renal function: BUN/CRE ≤ 1.5×ULN or endogenous creatinine clearance ≥ 60ml/min (Cockcroft-Gault formula); * No contraindications to chemotherapy or radiotherapy; * Inform consent form;
Exclusion criteria
* Have some PEG/PEJ contraindications, such as coagulopathy, recent anticoagulant medications and aspirin, gastric ulcer or history of gastric bleeding, portal hypertension combined with abdominal and esophageal fundal varices, pyloric obstruction due to residual stomach under the costal arch after various major gastrectomy or various reasons; * Distance metastases; * Have or are suffering from other malignant tumors; * Participating in other clinical trials; * Drug or alcohol addition; * Do not have full capacity for civil acts; * Mental disorder; * Pregnancy or lactation; * Severe complication, eg, uncontrolled hypertension;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of IBW% | 2 months | To observe the changes and differences in the incidence of the actual weight/ideal weight (IBW%) less than 90% during the treatment of the two groups of patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of WL、UBW% and BMI | 36 months | To observe the changes and differences in the incidence of body weight loss (WL)≥5%/10%, actual body weight/usual body weight (UBW%), body mass index (BMI) before, during and after treatment |
| Number of Participants With Abnormal Laboratory Values | 36 months | To observe patients' complete blood cell count and blood biochemical examination during the treatment and three years after the treatment. |
| Overall survival | 36 months | From date of recruited to death |
| Progression free survival | 36 months | From date of recruited to disease progression |
| Locoregional recurrence free survival | 36 months | From date of recruited to locoregional recurrence |
| Distant metastasis free survival | 36 months | From date of recruited to distant metastasis |
| Nutrition screening and evaluation | 36 months | To observe the changes and differences of nutrition screening and evaluation (NRS2002 and PG-SGA) before, during and after treatment in the two groups |
| Quality of life: EuroQoL 5 dimension | 36 months | Evaluating with questionnaire of EuroQoL 5 dimension, 5 level health state utility index (EQ-5D-5L) |
| Acute toxicities | through study completion, an average of 2 months | Evaluating with CTCAE v5.0 |
| Late toxicity | 36 months | assessed with Radiation Therapy Oncology Group radiation morbidity scoring criteria |
Countries
China
Contacts
CONTACTJingjing Miao, MD
PRINCIPAL_INVESTIGATORChong Zhao, MD
Sun Yat-Sen University Cancer Center
Outcome results
None listed